Zelapar (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00443872 (ClinicalTrials.gov) | March 2007 | 3/3/2007 | Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists | Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications | Parkinson's Disease | Drug: orally disintegrating selegiline (Zelapar) | Parkinson's Disease and Movement Disorder Center of Boca Raton | Valeant Pharmaceuticals International, Inc. | Completed | 30 Years | 90 Years | All | 77 | Phase 4 | United States |
| 2 | NCT00640159 (ClinicalTrials.gov) | January 2007 | 18/3/2008 | Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease | Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. | Parkinson's Disease | Drug: Zelapar | Baylor College of Medicine | NULL | Completed | 30 Years | 90 Years | Both | 55 | Phase 4 | United States |